Analyst Price Targets — CRNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 1:15 pm | Alex Thompson | Stifel Nicolaus | $85.00 | $83.50 | TheFly | Crinetics downgraded to Hold from Buy at Stifel |
| July 8, 2026 12:58 am | — | Evercore ISI | $85.00 | $83.53 | TheFly | Crinetics downgraded to In Line from Outperform at Evercore ISI |
| July 7, 2026 2:01 pm | — | Jefferies | $85.00 | $42.03 | TheFly | Crinetics downgraded to Hold from Buy at Jefferies |
| July 7, 2026 11:37 am | — | H.C. Wainwright | $85.00 | $42.03 | TheFly | Crinetics downgraded to Neutral from Buy at H.C. Wainwright |
| July 7, 2026 10:47 am | — | Robert W. Baird | $85.00 | $42.03 | TheFly | Crinetics price target raised to $85 from $62 at Baird |
| July 2, 2026 8:38 am | Ashwani Verma | UBS | $55.00 | $38.68 | TheFly | Crinetics initiated with a Buy at UBS |
| June 22, 2026 1:34 pm | Alex Thompson | Stifel Nicolaus | $83.00 | $36.06 | StreetInsider | Stifel Reiterates Buy Rating on Crinetics (CRNX) |
| June 15, 2026 10:48 am | Douglas Tsao | H.C. Wainwright | $81.00 | $34.47 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX) |
| May 15, 2026 12:22 pm | Gavin Clark-Gartner | Evercore ISI | $88.00 | $37.71 | TheFly | Crinetics price target lowered to $88 from $89 at Evercore ISI |
| May 11, 2026 11:54 am | — | Oppenheimer | $84.00 | $37.80 | TheFly | Crinetics price target lowered to $84 from $87 at Oppenheimer |
Latest News for CRNX
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRNX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.